233 related articles for article (PubMed ID: 37868997)
21. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
[TBL] [Abstract][Full Text] [Related]
22. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1
Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; Muruzabal JC; Alcaide J; Guillen-Grima F; Minguez JA; Amores-Tirado J; Gonzalez-Martin A; Sarobe P; Lasarte JJ; Ponz-Sarvise M; De Andrea CE; Hervas-Stubbs S
Br J Cancer; 2021 Mar; 124(6):1138-1149. PubMed ID: 33402737
[TBL] [Abstract][Full Text] [Related]
23. Expression of immune checkpoints in T cells of esophageal cancer patients.
Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
[TBL] [Abstract][Full Text] [Related]
24. Functional exhaustion of CD4
Ozkazanc D; Yoyen-Ermis D; Tavukcuoglu E; Buyukasik Y; Esendagli G
Immunology; 2016 Dec; 149(4):460-471. PubMed ID: 27565576
[TBL] [Abstract][Full Text] [Related]
25. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients.
Khalaf S; Toor SM; Murshed K; Kurer MA; Ahmed AA; Abu Nada M; Elkord E
Clin Immunol; 2020 Jun; 215():108429. PubMed ID: 32320745
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
Han GH; Hwang I; Cho H; Ylaya K; Choi JA; Kwon H; Chung JY; Hewitt SM; Kim JH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071938
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
29. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
30. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
Ye Q; Song DG; Poussin M; Yamamoto T; Best A; Li C; Coukos G; Powell DJ
Clin Cancer Res; 2014 Jan; 20(1):44-55. PubMed ID: 24045181
[TBL] [Abstract][Full Text] [Related]
31. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
32. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
Myklebust JH; Irish JM; Brody J; Czerwinski DK; Houot R; Kohrt HE; Timmerman J; Said J; Green MR; Delabie J; Kolstad A; Alizadeh AA; Levy R
Blood; 2013 Feb; 121(8):1367-76. PubMed ID: 23297127
[TBL] [Abstract][Full Text] [Related]
33. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
35. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
[TBL] [Abstract][Full Text] [Related]
36. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
37. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
38. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
39. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract][Full Text] [Related]
40. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]